NASDAQ · ALVO
Healthcare · Drug Manufacturers - Specialty & Generic
$5.85
Down-$0.18 (-3.08%)
Updated Oct 9, 2026, 12:49 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ALVO
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
ALVO closed at $5.85 after 20 trading sessions, up 11.64% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $6.10 | $6.14 | $5.845 | $5.85 | 864.57K |
| Oct 6, 2026 | $6.07 | $6.17 | $6.00 | $6.14 | 1.22M |
| Oct 5, 2026 | $5.99 | $6.53 | $5.90 | $6.11 | 2.9M |
| Oct 2, 2026 | $5.61 | $5.70 | $5.43 | $5.45 | 750.93K |
| Oct 1, 2026 | $5.81 | $5.82 | $5.46 | $5.62 | 1.2M |
| Sep 30, 2026 | $5.95 | $5.97 | $5.76 | $5.80 | 1.14M |
| Sep 29, 2026 | $6.135 | $6.17 | $5.825 | $5.92 | 1.17M |
| Sep 28, 2026 | $5.73 | $6.17 | $5.675 | $6.15 | 1.44M |
| Sep 25, 2026 | $5.90 | $5.90 | $5.67 | $5.75 | 705.19K |
| Sep 24, 2026 | $5.75 | $6.06 | $5.75 | $5.88 | 1.2M |
| Sep 23, 2026 | $5.86 | $5.89 | $5.70 | $5.81 | 774.27K |
| Sep 22, 2026 | $5.90 | $5.97 | $5.715 | $5.84 | 978.06K |
| Sep 21, 2026 | $5.92 | $5.98 | $5.74 | $5.88 | 1.31M |
| Sep 18, 2026 | $5.40 | $5.985 | $5.395 | $5.87 | 3.54M |
| Sep 17, 2026 | $5.22 | $5.455 | $5.20 | $5.34 | 1.71M |
| Sep 16, 2026 | $5.40 | $5.53 | $5.10 | $5.10 | 3.87M |
| Sep 15, 2026 | $5.05 | $5.07 | $4.90 | $5.02 | 610.03K |
| Sep 14, 2026 | $5.225 | $5.26 | $5.035 | $5.05 | 674.19K |
| Sep 11, 2026 | $5.28 | $5.39 | $5.26 | $5.29 | 667.87K |
| Sep 10, 2026 | $5.21 | $5.34 | $5.14 | $5.24 | 540.86K |
The latest Smart Investors Daily articles mentioning ALVO.
Company
Market Activity
Research & News
ALVO research
Company profile and research snapshot.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | Barclays | Overweight | — |
| Aug 24, 2026 | B of A Securities | Buy | — |
| Aug 14, 2026 | Evercore ISI Group | Outperform | — |
| Mar 24, 2026 | UBS | Buy | — |
| Mar 24, 2026 | Barclays | Underweight | — |
No generated briefing is available yet.
Benzinga · Oct 5, 2026
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suitesFurther confirms resolution of FDA inspection-related matters at the
Yahoo · Sep 16, 2026
The biotech company’s stock rises after Barclays gives it a double upgrade, citing confidence in upcoming FDA approvals.
Yahoo · Sep 16, 2026
Barclays analyst Glen Santangelo raised the stock to Overweight from Underweight and lifted his target to $8 from $4.
ChartMill · Sep 16, 2026
Let's have a look at the gap up and gap down stocks in today's session.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALVO.
